LV11971B - Pirolidīnhidroksāmskābes atvasinājumi un to iegūšanas paņēmiens - Google Patents

Pirolidīnhidroksāmskābes atvasinājumi un to iegūšanas paņēmiens Download PDF

Info

Publication number
LV11971B
LV11971B LVP-97-203A LV970203A LV11971B LV 11971 B LV11971 B LV 11971B LV 970203 A LV970203 A LV 970203A LV 11971 B LV11971 B LV 11971B
Authority
LV
Latvia
Prior art keywords
hydroxy
phenyl
acetamide
hydrogen
compound
Prior art date
Application number
LVP-97-203A
Other languages
English (en)
Other versions
LV11971A (lv
Inventor
Fumitaka Ito
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of LV11971A publication Critical patent/LV11971A/lv
Publication of LV11971B publication Critical patent/LV11971B/lv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Claims (13)

1LV 11971 Izgudrojuma formula 1. Savienojums ar formulu (I), Ar
A ir ūdeņraža atoms, hidroksilgrupa vai OY, kur Y ir hidroksilgrupas aiz-sarggrupa; Ar ir fenilgrupa, kas neobligāti aizvietota ar vienu vai vairākiem aizvietotājiem no rindas: halogēna atoms, hidroksilgrupa, Ci^alkilgrupa, Ci^alk-oksigrupa, trifluormetilgrupa, Ci^alkoksi-Ci^alkoksigrupa un karboksil-aizvietota Ci^alkoksigrupa; X ir fenilgrupa, naftilgrupa, bifenilgrupa, indanilgrupa, benzofuranilgrupa, benzotienilgrupa, 1-oksotetralin-6-iigrupa, Ci-*alkilendioksigrupa, piri-dinilgrupa, furanilgrupa vai tienilgrupa, pie kam minētas grupas neobligāti aizvietotas ar 1 - 3 aizvietotājiem no rindas: halogēna atoms, Ci^alkilgrupa, Ci^alkoksigrupa, hidroksilgrupa, nitrogrupa, trifluormetilgrupa un metilsulfonilgrupa; R ir ūdeņraža atoms, Ci^alkilgrupa vai hidroksilgrupas aizsarggrupa, kā arī minētā savienojuma sālis.
2. Savienojums pēc 1. punkta, kurā A ir ūdeņraža atoms vai hidroksilgrupa; R ir ūdeņraža atoms vai C-Malkilgrupa.
3. Savienojums pēc 2. punkta, kurā Ar ir fenilgrupa. 2
4. Savienojums pēc 3. punkta, kurā X ir fenilgrupa, kas aizvietota ar 1 - 3 aizvietotājiem no rindas: hlora atoms, metilgrupa un trifluormetilgrupa; R ir ūdeņraža atoms.
5. Savienojums pēc 4. punkta, kurā X ir 3,4-dihlorfenilgrupa.
6. Savienojums pēc 4. punkta, kas ņemts no rindas: 2-(3,4-dihlorfenil)-N-hidroksi-N-[1-(S)-fenil-2-(1-pirolidinil)etilļacetamTds; 2-(2,3,6-trihlorfenil)-N-hidroksi-N-[1-(S)-fenil-2-(1-pirolidinil)etil]acetamTds; 2-(4-trifluormetilfenil)-N-hidroksi-N-[1-(S)-fenil-2-(1-pirolidinil)etiljacetamīds; 2-(2,4,6-trimetilfenil)-N-hidroksi-N-[1-(S)-fenil-2-(1-pirolidinil)etilļacetamīds; 2-(3,4-dihlorfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feni!etii]- acetamīds; 2-{4-bromfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]- acetamīds; 2-(4-trifluormetilfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]- acetamīds; 2-(4-hlorfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletilj- acetamīds; 2-(2,3-dihlorfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]- acetamīds; 2-(2,4-dihlorfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]- acetamTds; 2-(2,5-dihlorfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]- acetamīds; 2-(2,6-dihlorfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletilļ- acetamīds; 2-(2,3,6-trihlorfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]- acetamīds; 2-(3,4-dihlorfenil)-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]-acetamīds; 2-(3,4-dimetilfenil)-N-hidroksi-N-[2-(3-(S)-hidroksipirolidin-1-il)-1-(S)-feniletil]- acetamTds. 3 LV 11971
7. Savienojums pēc 1. punkta, kurā A ir OY un R ir hidroksilgrupas aizsarggrupa no rindas: benzilgrupa, trifenilmetilgrupa, tetrahidropiranilgrupa, metoksimetilgrupa un R1R2R3Si- grupa, kur katrs no R1, R2 un Rs ir Ci^alkil-grupa vai fenilgrupa.
8. Farmaceitiskā kompozīcija, kas satur savienojumu pēc 1. punkta un farmaceitiski inertu nesēju, un kas pielietojama kā analgētisks, pretiekaisuma, diurētisks, anestētisks, neiroprotektīvs līdzeklis, līdzeklis triekas ārstēšanai vai līdzeklis tādu funkcionālu zarnu slimību kā vēdersāpju ārstēšanai.
9. Savienojuma pēc 1. punkta pielietojums tādu ārstniecības līdzekļu ražošanai, kas paredzēti tādu zīdītājus slimību ārstēšanai, kurās nepieciešams kapa-receptora agonists.
10. Savienojums ar formulu (II), Ar
kurā: A ir ūdeņraža atoms, hidroksilgrupa vai OY, kur Y ir hidroksilgrupas aizsarggrupa Ar ir fenilgrupa, neobligāti aizvietota ar vienu vai vairākiem aizvietotājiem no rindas: halogēna atoms, hidroksilgrupa, Ci^alkilgrupa, Ci^alkoksi-grupa, trifluormetilgrupa, Ci^alkoksi-Ci^alkoksigrupa un karboksilaizvie-tota C-Malkoksigrupa; R ir ūdeņraža atoms, Ci^alkilgrupa vai hidroksilgrupas aizsarggrupa.
11. Paņēmiens savienojuma ar formulu (II) iegūšanai, kas ietver etanolamīna (III) reakciju ar hidroksilamīna atvasinājumu (IV),
(V) 4 kuru tālāk apstrādā ar metānsulfonilhlorīdu bāzes klātbūtnē, un pēc tam pievieno aizsargātu hidroksilamīnu, noslēgumā, ja nepieciešams, nošķeļot aizsarggrupu.
12. Paņēmiens savienojuma ar formulu (II) iegūšanai, kas ietver pirolidTna ar formulu (VII) apstrādi ar aizvietotu vai neaizvietotu feniloksirānu (VIII),
O (vil) (vm) veidojot savienojumu (IX) un (X) maisījumu,
kuru apstrādā ar metānsulfonilhlorīdu bāzes klātbūtnē un pievieno aizsargātu hidroksilamīnu, noslēgumā, ja nepieciešams, nošķeļot aizsarggrupu.
13. Paņēmiens savienojuma ar formulu (I) iegūšanai, kas ietver savienojuma ar formulu (II), kurā R ir hidroksilgrupas aizsarggrupa, apstrādi ar karbonskābi XCH2COOH, aizsarggrupas atšķelšanu, un, ja nepieciešams, iegūtā savienojuma alkilēšanu.
LVP-97-203A 1995-03-31 1997-10-21 Pirolidīnhidroksāmskābes atvasinājumi un to iegūšanas paņēmiens LV11971B (lv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9500631 1995-03-31
PCT/JP1996/000820 WO1996030339A1 (en) 1995-03-31 1996-03-28 Pyrrolidinyl hydroxamic acid compounds and their production process

Publications (2)

Publication Number Publication Date
LV11971A LV11971A (lv) 1998-02-20
LV11971B true LV11971B (lv) 1998-06-20

Family

ID=14125824

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-97-203A LV11971B (lv) 1995-03-31 1997-10-21 Pirolidīnhidroksāmskābes atvasinājumi un to iegūšanas paņēmiens

Country Status (35)

Country Link
US (2) US5952369A (lv)
EP (1) EP0817772B1 (lv)
JP (1) JP3035356B2 (lv)
KR (1) KR100258657B1 (lv)
AP (1) AP625A (lv)
AR (1) AR002729A1 (lv)
AT (1) ATE231840T1 (lv)
AU (1) AU693336B2 (lv)
BG (1) BG62611B1 (lv)
BR (1) BR9607750A (lv)
CA (1) CA2213815C (lv)
CZ (1) CZ306497A3 (lv)
DE (1) DE69626009T2 (lv)
DK (1) DK0817772T3 (lv)
ES (1) ES2188743T3 (lv)
HR (1) HRP960141A2 (lv)
HU (1) HUP9900767A3 (lv)
IL (2) IL117440A0 (lv)
IS (1) IS4547A (lv)
LV (1) LV11971B (lv)
MA (1) MA23832A1 (lv)
NO (1) NO974513L (lv)
NZ (1) NZ304113A (lv)
OA (1) OA10518A (lv)
PE (1) PE43397A1 (lv)
PL (1) PL322652A1 (lv)
RU (1) RU2144917C1 (lv)
SI (1) SI9620039A (lv)
SK (1) SK129897A3 (lv)
TN (1) TNSN96045A1 (lv)
TR (1) TR199701082T1 (lv)
TW (1) TW408111B (lv)
WO (1) WO1996030339A1 (lv)
YU (1) YU18696A (lv)
ZA (1) ZA962476B (lv)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9701042A (es) * 1996-02-07 1998-05-31 Pfizer Compuestos del acido hidroxamico.
TNSN97092A1 (ar) * 1996-09-18 1999-12-31 Agouron Pharma مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.
CA2273253C (en) * 1996-12-02 2003-09-16 Kyorin Pharmaceutical Co., Ltd. Novel n-substituted pyrrolidine derivatives and process for preparing the same
CA2276074A1 (en) * 1997-01-10 1998-07-16 Merck & Co., Inc. Efficient synthesis of a chiral mediator
IL130429A0 (en) * 1998-08-24 2000-06-01 Pfizer Prod Inc Process for preparing pyrrolidinyl hydroxamic acid compounds
KR100295740B1 (ko) * 1998-09-17 2001-11-05 박영구 N-치환된-하이드록시고리화알킬아민유도체의제조방법
US6444829B1 (en) * 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
AU2002247886A1 (en) 2001-04-30 2002-11-11 Pfizer Products Inc. Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
AU2003269399A1 (en) * 2002-11-01 2004-05-25 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
GB0821010D0 (en) * 2008-11-17 2008-12-24 Univ Warwick Plant development control composition
EP2709985B1 (en) 2011-05-16 2017-10-04 Bionomics Limited Amine derivatives as potassium channel blockers
CA2866299C (en) * 2012-03-05 2017-12-05 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists
GB201210395D0 (en) * 2012-06-11 2012-07-25 Syngenta Participations Ag Crop enhancement compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3268539A (en) * 1963-05-20 1966-08-23 Universal Oil Prod Co Tertiary-aminoalkyl derivatives of diaryl substituted acetohydroxamic acid esters

Also Published As

Publication number Publication date
IS4547A (is) 1997-08-19
AR002729A1 (es) 1998-04-29
JPH11501048A (ja) 1999-01-26
YU18696A (sh) 1999-06-15
BG101896A (en) 1999-01-29
CA2213815C (en) 2001-12-18
NO974513D0 (no) 1997-09-29
DK0817772T3 (da) 2003-05-19
HUP9900767A2 (hu) 1999-07-28
US5952369A (en) 1999-09-14
PL322652A1 (en) 1998-02-16
OA10518A (en) 2002-04-22
US6110947A (en) 2000-08-29
CA2213815A1 (en) 1996-10-03
MX9707454A (es) 1998-07-31
TR199701082T1 (xx) 1998-02-21
WO1996030339A1 (en) 1996-10-03
KR19980703476A (ko) 1998-11-05
NO974513L (no) 1997-09-29
BG62611B1 (bg) 2000-03-31
ATE231840T1 (de) 2003-02-15
HRP960141A2 (en) 1997-10-31
TNSN96045A1 (fr) 2005-03-15
TW408111B (en) 2000-10-11
DE69626009D1 (de) 2003-03-06
RU2144917C1 (ru) 2000-01-27
AP9600791A0 (en) 1996-04-30
SI9620039A (sl) 1998-08-31
HUP9900767A3 (en) 2001-01-29
MA23832A1 (fr) 1996-10-01
EP0817772A1 (en) 1998-01-14
LV11971A (lv) 1998-02-20
EP0817772B1 (en) 2003-01-29
IL117440A0 (en) 1996-07-23
AU5121196A (en) 1996-10-16
ZA962476B (en) 1997-09-29
NZ304113A (en) 1999-01-28
SK129897A3 (en) 1998-11-04
AU693336B2 (en) 1998-06-25
BR9607750A (pt) 1998-06-30
DE69626009T2 (de) 2003-08-14
IL129479A0 (en) 2000-02-29
CZ306497A3 (cs) 1998-07-15
AP625A (en) 1997-12-24
ES2188743T3 (es) 2003-07-01
PE43397A1 (es) 1997-10-13
KR100258657B1 (ko) 2000-07-01
JP3035356B2 (ja) 2000-04-24

Similar Documents

Publication Publication Date Title
RU2125041C1 (ru) Арилацетамиды, способ их получения, фармацевтическая композиция и способ ее получения
US5071859A (en) N-substituted azaheterocyclic carboxylic acids and pharmaceutical uses
EP0817772B1 (en) Pyrrolidinyl hydroxamic acid compounds and their production process
Jackson et al. A New Approach to the Synthesis of. beta.-Hydroxy-. alpha.-amino Acids Using (Arylthio) nitrooxiranes
KR101124098B1 (ko) 2-옥소-1-피롤리딘 유도체를 제조하는 방법
KR100523184B1 (ko) 아제티딘 및 피롤리딘의 유도체
JP2935899B2 (ja) ▲下k▼レセプターアゴニストとしてのn−(2−(ピロリジニル−1)−1−フェニルエチル)アセトアミド
FR2729142A1 (fr) Nouvelles amines heterocycliques, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques
NZ233002A (en) 3-(aminoalkyl)benzothiopyran derivatives and pharmaceutical compositions
EP0789021B1 (en) Hydroxamic acid compounds as opioid kappa receptor agonists
MXPA97007454A (en) Hydroxamic pirrolidinil acid compounds and their product procedure
US5214057A (en) N-substituted azaheterocyclic carboxylic acids
JP2012107006A (ja) N−置換−環状アミノ誘導体の製造方法
PT789021E (pt) Compostos de acido pirrolidinil hidroxamico e o processo para a sua producao